Travere Therapeutics, Inc. specializes in treatments for rare and life-threatening diseases with significant unmet medical needs. The company's commercial portfolio is anchored by FILSPARI (sparsentan), which targets critical pathways in the progression of rare kidney disorders. Its other marketed products include Thiola and Thiola EC for cystinuria, Chenodal for radiolucent stones in gallbladders, and Cholbam for bile acid synthesis disorders. In addition to its approved medications, Travere's clinical pipeline features pegtibatinase, an investigational human enzyme replacement therapy for classical homocystinuria. The company operates primarily in the United States, generating revenue by selling its medicines to specialty pharmacies, hospitals, and specialists. Travere also collaborates with patient advocacy organizations and academic research centers to advance its rare disease programs.
